Cost-effectiveness analysis of ribociclib plus an aromatase inhibitor versus abemaciclib plus endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer: a Canadian payer perspective.
Aim: Ribociclib and abemaciclib, cyclin-dependent kinase 4/6 inhibitors, are adjuvant treatments for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). In the Phase III NATALEE trial, ribociclib plus an aromatase inhibitor (AI) significantly improved in...